Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents

Bibliography

• BUTCHER EC: Leukocyte-endothelial cell recognition-three (or more) steps to specificity and diversity. Cell (1991) 67:1033–1036.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Ann. Rev. Physiol. (1995) 57:827–872.
   PubMed Web of Science ®Google Scholar
• ALI H, HARIBABU B, RICHARDSON RM et al.: Mechanism of inflammation and leukocyte activation. Med. Clin. North Am. (1997) 81:1–28.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346:425–434.
   PubMed Web of Science ®Google Scholar
• •An excellent introductory review from the leader in the leukocyte field.
   Google Scholar
• BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60–66.
   PubMed Web of Science ®Google Scholar
• LEY K Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc. Res. (1996) 32:733–742.
   PubMed Web of Science ®Google Scholar
• GREEN JM, ZHENG XG, SIMIZU Yet al.: T cell receptor stimulation, but not CD28 costimulation, is dependent on LFA-1-mediated events. Eur. J. Immunology (1994) 24:265–272.
   Google Scholar
• KISHIMOTO TK, ROTHLEIN R Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv. Pharmacol. (1994) 25:117–169.
   PubMedGoogle Scholar
• HYNES RO: Integrins: versatility, modulation, and signalling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• MAZZONE A, RICEVUTE G: Leukocyte CD11/CD18 integrins: biological and clinical relevance. HaematoL (1995) 80:161–175.
   PubMed Web of Science ®Google Scholar
• GAHMBERG CG: Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr. Opin. Cell Biol. (1997) 9:643–650.
   PubMed Web of Science ®Google Scholar
• •A concise and up-to-date overview of the structures, binding sites, and activation of leukocyte integrins and of intercellular adhesion molecules, and the role of leukocyte adhesion molecules in disease.
   Google Scholar
• CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood (1994) 84:2068–2101.
   PubMed Web of Science ®Google Scholar
• •A thorough general review of the structures, activation, and signalling of adhesion molecules.
   Google Scholar
• GAHMBERG CG, TOLVANEN M, KOTOVUORI P: Leukocyte adhesion-structure and function of human leukocyte 132-integrins and their cellular ligands. Eur. J. Biochem. (1997) 245: 215–232.
   PubMedGoogle Scholar
• LANDIS RC, McDOWALL A, HOLNESS CL et al.: Involvement of the 'I' domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. J. Cell Biol. (1994) 126:529–537.
   PubMed Web of Science ®Google Scholar
• ANDERSON DC, SCHMALSTIEG FC, SHEARER Wet al.: Leukocyte LFA-1, OKM1, p150,95 deficiency syndrome: functional and biosynthetic studies of three kindreds. Fed. Proc.. (1985) 44:2671–2677.
   Google Scholar
• SLIGH JE, BALLANTYNE CM, RICH SS et al.: Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc. NatL Acad USA (1993) 90:8529–8533.
   PubMed Web of Science ®Google Scholar
• SCHMITS R, KÜNDIG TM, BAKER DM et al.: LFA-1 deficient mice show normal CTL responses to virus but fail to reject immunogenic tumour./ Exp. Med (1996) 183:1415–1426.
   Google Scholar
• BEVILACQUA MP, NELSON RM, MANNORI G: Endothelial-leukocyte adhesion molecules in human disease. Ann. Rev. Med. (1994) 45:361–378.
   PubMed Web of Science ®Google Scholar
• HUANG Y-W, BALUNA R, VISETTA ES: Adhesion molecules as targets for cancer therapy. HistoL Histopathol. (1997) 12:467–477.
   PubMed Web of Science ®Google Scholar
• CORNEJO CJ, WINN RK, HARLAN JM: Anti-adhesion therapy. Adv. Pharmacol. (1997) 39:99–142.
   PubMedGoogle Scholar
• HENRICKS PA, NIJKAMP FP: Pharmacological modulation of cell adhesion molecules. Eur. J. Pharmacol. (1998) 344:1–13.
   PubMed Web of Science ®Google Scholar
• JORDAN JE, ZHAO ZQ, VINTEN-JOHANSEN J: The role of neutrophils in myocardial ischaemia-reperfiision injury. Cardiovasc. Res. (1999) 43:860–878.
   PubMed Web of Science ®Google Scholar
• COSIMI A, CONTI D, DELMONICO F et al.: In vivo effects of monoclonal antibody to ICAM-1(CD54) in nonhuman primates with renal allografts. J. Immunol. (1990) 144:4604–4612.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37:992–999.
   PubMed Web of Science ®Google Scholar
• CAVAZZANA-CALVO M, BORDIGONI P, MICHEL G et al.: A Phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Societe Francaise de Greffe de Moelle Osseuse. Br.J. Haematol. (1996) 93:131–138.
   PubMed Web of Science ®Google Scholar
• NAKAKURA EK, SHORTHOUSE RA, ZHENG B et al.: Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation (1996) 62:547–552.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB A, KRUEGER JG, BRIGHT R et al.: Effects of administration of a single dose of a humanized monoclonal antibody to CD1 la on the immunobiology and clinical activity of psoriasis. J. Am. Acad DermatoL (2000) 42:428–435.
   PubMed Web of Science ®Google Scholar
• RHEE P, MORRIS J, DURHAM R et al.: Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group. J. Trauma (2000) 49:611-619; discussion 619–620.
   Google Scholar
• KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS et al.: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion moleculel monoclonal antibody. Arthritis Rheum. (1997) 40:849–853.
   PubMed Web of Science ®Google Scholar
• HAMILTON GS, MEWSHAW RE, BRYANT CM et al.: Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes. J. Med. Chem. (1995) 38:1650–1656.
   PubMed Web of Science ®Google Scholar
• BOSCHELLI DH,KRAMER JB, KHATANA SS et al.: E-selectin, ICAM-1, and VCAM-1-mediated cell adhesion by benzo [b] thiophene-, benzofuran-, indole-, and naphthalene-2-carboxamides: Identification of PD 144795 as an anti-inflammatory agent. J. Med. Chem. (1995) 38:4597–4614.
   Google Scholar
• SANFILIPPO PJ, JETTER MC, CORDOVA R et al.: Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion. J. Med. Chem. (1995) 38: 1057–1059.
   PubMed Web of Science ®Google Scholar
• •The first reported small molecule selective LFA-1/ICAM-1 antagonist.
   Google Scholar
• GADEK TR, MARSTERS Jr. JC, STANLEY M et al.: Identification and characterization of antagonists of the LFA-1/ ICAM-1 protein-protein interaction as novel immunomodulatory agents. 220th ACS National Meeting, Washington DC, U.S.A. (2000) MEDI 177,
   Google Scholar
• KELLY TA, JEANFAVRE DD, MeNEIL DW et al.: A small molecule antagonist of LFA-1-mediated cell adhesion. J. ImmunoL (1999) 163:5173–5177.
   PubMed Web of Science ®Google Scholar
• •Detailed account of the discovery and characterization of BIRT 377.
   Google Scholar
• EMEIGH JE, BORMANN B-J, FRYE Let al.: Small molecule antagonists of LFA-1-mediated cell adhesion. MEDI 177, 221st ACS National Meeting, 2001 San Diego, CA. U.S.A.
   Google Scholar
• LIU G, LINK JT, PEI Z et al.: Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/ intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J. Med. Chem. (2000) 43:4025–4040.
   Google Scholar
• LIU G, HUTH JR, OLEJNICZAK ET et al.: Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1 /intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. (2001) 44:1202–1210.
   Google Scholar
• •The report ofp-arylthio cinnamide-based antagonists binding to the IDAS using both NMR spectroscopy and molecular modelling studies.
   Google Scholar
• PEI Z, XIN Z, LIU G et al.: Discovery of potent antagonists of leukocyte function-associated antigen- 1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) SAP. and improvement of overall properties ofp-arylthio cinnamides. J. Med. Chem. (2001) In press.
   Google Scholar
• LINK JT, SORENSEN B, LIU G et al.: Discovery and SAP. of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists. Bioorg. Med. Chem. Lett. (2001) 11:973–976.
   Google Scholar
• NAKANO T, KOIWA T, TAKAHASHI S: Adxanthromycins A and B, new inhibitors of ICAM-1/ICAM-1 mediated cell adhesion molecule from Streptomyces sp. NA-148. 1. Taxonomy, production, isolation and biological activities. J. Antibiot. (Tokyo) (2000) 53:12–18.
   Google Scholar
• HUANG C, SPRINGER TA: A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J. Bid. Chem. (1995) 270:19008–19016.
   PubMed Web of Science ®Google Scholar
• LEITINGER B, HOGG N: Effects of I domain deletion on the function of the beta 2 integrin lymphocyte function-associated antigen-1. MoL Bio. Cell (2000) 11:677–690.
   PubMed Web of Science ®Google Scholar
• STANLEY P, HOGG N: The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 but not Gln-73. J. Biol. Chem. (1998) 273:3358–3362.
   PubMed Web of Science ®Google Scholar
• FISHER KL, LU J, RIDDLE Let al.: Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1. MoL Biol. Cell (1997) 8:501–515.
   Google Scholar
• •This article reported the identification of the residues involved in interacting with LFA-1 I domain through extensive mutagenesis and the creation of a working model for designing ICAM-1 first Ig domain mimetics.
   Google Scholar
• BELLA J, KOLATKAR PR, MARLOR CW et al.: The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. USA (1998) 95:4140–4145.
   PubMed Web of Science ®Google Scholar
• EDWARDS CP, FISHER KL, PRESTA LG et al.: Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1. J. Biol. Chem. (1998) 273:28937–28944.
   PubMed Web of Science ®Google Scholar
• BINNERTS ME, Van KOOYKY: How LFA-1 binds to different ligands. ImmunoL Today (1999) 20:240–245.
   PubMedGoogle Scholar
• VAN KOOYKY, FIGDOR CG: Avidity regulation of integrins: the driving force in leukocyte adhesion. Curr. Opin. Cell Biol. (2000) 12:542–547.
   PubMed Web of Science ®Google Scholar
• LEE JO, RIEU P, ARNOUT MA et aL: Crystal structure of the a domain from the a-subunit of the integrin CR3 (CD1 lb/ CD18). Cell (1995) 80:631–638.
   PubMed Web of Science ®Google Scholar
• LEE JO, BUNKSTON LA, ARNOUT MA. et al.: Two conformations of the integrin A-Domain (I-domain): a pathway for activation? Structure (1995) 3:1333–1340.
   Google Scholar
• QUA, LEAHY DJ: Crystal Structure of the I-domain from CD1 la/CD18. Proc. Natl. Acad. Sci. USA (1995) 92:10277–10281.
   PubMed Web of Science ®Google Scholar
• QUA, LEAHY DJ: The role of the divalent cation in the structure of the I-Domain from the CD1 la/CD18 integrin. Structure (1996) 4:931–942.
   PubMed Web of Science ®Google Scholar
• EMSLEY J, KNIGHT CG, FARNDALE R et al.: Structural basis of collagen recognition by integrin a2131. Cell (2000) 101:47–56.
   PubMed Web of Science ®Google Scholar
• HUTH JR, OLEJNICZAK ET, MENDOZA R et aL: NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen-1 ligand binding. Proc. Natl. Acad. Sci. USA (2000) 97:5231–5236.
   PubMed Web of Science ®Google Scholar
• ••This is the article that proposed an IDASsite distal from the MIDAS within the I domain using NMR and site-directed mutagenesis techniques.
   Google Scholar
• KALLEN J, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD1 1 a I-domain. J. MoL Biol. (1999) 292:1–9.
   PubMed Web of Science ®Google Scholar
• •Structural biology studies using both x-ray crystallography and NMR spectroscopy established the binding site of lovastatin, which coincides with the proposed IDAS.
   Google Scholar
• LU C, SHIMAOKA M, FERZLY M et al.: An isolated, surface-expressed I domain of the integrin aL132 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. USA (2001) 98:2387–2392.
   PubMed Web of Science ®Google Scholar